WALTHAM, Mass., July 31 Repligen Corporation(Nasdaq: RGEN) announced today that the Company President and Chief ExecutiveOfficer, Walter C. Herlihy, Ph.D., will host a conference call and webcast onThursday, August 7th, 2008 at 11:00 a.m. EDT, to report first quarter fiscalyear 2009 financial results and to provide a quarterly update of the Company.
This call is being webcast by Thomson/CCBN and can be accessed viaRepligen's website at http://www.repligen.com. If you are unable to accessthe webcast via the internet, you may also listen to the live broadcast bycalling (866) 761-0748 for domestic calls and (617) 614-2706 for internationalcalls. Participants must provide the following passcode: 62772305. For thosewho cannot participate in the live conference call, an archive of the audiowebcast will be available shortly after the call and may be accessed athttp://www.repligen.com.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on thedevelopment of novel therapeutics for neurological disorders. In addition, weare the world's leading supplier of recombinant Protein A, the sales of whichpartially fund the advancement of our development pipeline while supportingour financial stability. Repligen's corporate headquarters are located at 41Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additionalinformation may be requested from http://www.repligen.com.
This press release contains forward-looking statements which are madepursuant to the safe harbor provisions of Section 27A of the Securities Act of1933, as amended, and Section 21E of the Securities Exchange Act of 1934, asamended. The forward-looking statements in this release do not constituteguarantees of future performance. Investors are cautioned that statements inthis press release which are not strictly historical statements, including,without limitation, statements regarding current or future financialperformance and position, management's strategy, plans and objectives forfuture operations, plans and objectives for product development, plans andobjectives for present and future clinical trials and results of such trials,plans and objectives for regulatory approval, litigation, intellectualproperty, product development, manufacturing plans and performance such as theanticipated growth in the monoclonal antibody market and our other targetmarkets and projected growth in product sales, constitute forward-lookingstatements. Such forward-looking statements are subject to a number of risksand uncertainties that could cause actual results to differ materially fromthose anticipated, including, without limitation, risks associated with: thesuccess of current and future collaborative relationships, the marketacceptance of our products, our ability to compete with larger, betterfinanced pharmaceutical and biotechnology companies, new approaches to thetreatment of our targeted diseases, our expectation of incurring continuedlosses, our uncertainty of product revenues and profits, our ability togenerate future revenues, our ability to raise additional capital to continueour drug development programs, the success of our clinical trials, our abilityto develop and commercialize products, our ability to obtain requiredregulatory approvals, our compliance with all Food and Drug Administrationregulations, our ability to obtain, maintain and protect intellectual propertyrights for our products, the risk of litigation regarding our intellectualproperty rights, our limited sales and manufacturing capabilities, ourdependence on third-party manufacturers and value added resellers, our abilityto hire and retain skilled personnel, our volatile stock price, and otherrisks detailed in Repligen's filings with the Securities and ExchangeCommission. Repligen assumes no obligation to update any forward-lookinginformation contained in this press release or with re